Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
AAD, Academy, accuracy, Acorda, Affentranger, Afsaneh, Alavi, albumin, alfa, ALX, anaphylatoxin, antigen, apremilast, ascending, asunercept, atezulizumab, Bain, baricitinib, beleggen, beta, BTK, Burton, buyer, carbon, CDO, cemiplimab, cephalosporin, chemical, chemotherapeutic, Chinese, cleantech, climate, clindamycin, concomitantly, cosibelimab, COSO, Cox, CPAP, cream, CSO, customarily, CXC, cybersecurity, cyclic, cytochrome, cytotoxic, dapsone, dataset, delivery, Dentistry, depemokimab, depiction, depressed, descedent, deteriorate, dialogue, disqualification, disruptor, Division, downturn, doxorubicin, drempel, dynamic, editing, effectual, ELR, en, EP, etrasimod, expressly, extracellular, extraordinary, extrapolated, fuel, furlough, fusion, gas, gave, gemcitabine, gene, genital, geopolitical, Gohibic, graph, greenhouse, grondslag, hamster, harmour, hazard, heart, heffingvrij, hemoglobinuria, HHS, hydrolase, ICT, imiquimod, immunoglobulin, imsidolimab, inkomen, insertion, Instruction, intralesionally, intramuscular, Intratumorally, invasively, ipilimumab, izokibeb, JAK, junior, Lastly, Leqembi, leukotriene, locoregional, logistic, logistical, LTI, MAP, Maraba, Mayo, meantime, media, Mei, MEK, melanoma, metabolism, metronidazole, micro, microtubule, military, monovalent, moratlity, mucin, myeloid, nangibotide, nanobody, nanrilkefusp, necessitating, neurological, neutropenia, nihil, NMPA, Noncurrent, nondepleting, nuclear, oil, oncolytic, orimsilast, orismilast, ORR, PANAMO, peildatum, Pemphigoid, people, peptide, peptidic, persistent, Peter, photoimmune, plasmin, Po, postpone, povorcitinib, printed, pustular, radical, radiological, regression, remibrutinib, rendement, rendementspercentage, reproduce, resistant, resorcinol, rifampicin, RIST, Road, robust, route, routine, ruxolitinib, sabizabulin, Samsung, sefe, sentiment, serum, session, shutdown, sixty, sonelokimab, spanning, sparen, spesolimab, Spinraza, stagnation, stipulated, stratification, subpopulation, subunit, sudden, summer, superagonist, superficial, synthetic, Tai, tapered, taxane, Tecfidera, tetracycline, thrombin, timeframe, timeline, tirbanibulin, tocilizumab, tolearated, tow, transgenic, trap, trivalent, tyrosine, unapproved, unexercised, unlocked, unqualified, unresectable, untreated, vector, vegetative, Veru, Vilwaysi, voordeel, wage, Ward, Western, wouldthen, zilicoplan, zunsemetinib
Removed:
abbvie, absolute, absorb, Affentrager, aggregation, al, Ammann, ANCOVA, Anstalt, arithmetic, Asia, asserted, attached, attest, avoided, Bausch, biopharma, Biovitrum, brand, characterize, chemocentryx, Chugai, CIMA, Cloud, conference, confirmation, congregating, convince, costimulation, degranulation, detrimental, DF, diagnosed, discretionary, DLQI, drop, easier, economy, elaborated, eleven, emergent, epyx, escalating, escalation, exacerbation, execution, expedited, explained, extendable, ffentlichen, fistula, Floor, Florida, France, functionality, Gall, Genentech, genitalia, globally, golden, graft, greatest, ground, grouped, handled, Hao, hindered, historic, host, Humira, Hurley, impacting, impairing, imputation, Incyte, insentia, internet, Investco, IXCHANGE, IXPLORE, Janssen, Japanese, Katrin, KfW, Kung, lab, LANexpert, Lina, LP, Ma, machinery, mandated, manuscript, medium, MINE, minimal, missing, MoA, modelling, moving, multicenter, nancial, nodule, nonbinding, numerical, NY, observational, offered, Ohio, OLE, oncology, Ortho, outbreak, parachute, path, percent, petition, Pharma, pharmacodynamic, poster, precautionary, preceded, prioritization, promoter, QUALITATIVE, QUANTITATIVE, quicker, ra, reform, remediation, Remicade, remote, remotely, rendementgrondslag, RESERVED, revealed, revision, rheumatoid, Ritximab, rose, Russia, Salix, SB, Schweiz, SILIQ, Sloan, solve, Squibb, stable, strongest, subset, surprisingly, suspending, Swedish, switching, tailored, TEAE, Technologie, terrorism, thousand, transitioning, translate, twelve, unblinding, unwilling, Uschmann, visit, Wang, war, weaken, weakened, weakening, weekly, Wilcoxon, window, Yautong, York, Zurich
Filing tables
Filing exhibits
- 20-F Annual report (foreign)
- 1.1 Articles of Association of Inflarx N.V., Dated August 25, 2021
- 2.4 Description of Rights of Each Applicable Class of Securities Registered Under Section 12 of the Securities Exchange Act of 1934.
- 4.4 Addendum No. 2, Dated As of November 9, 2022, Between Inflarx GMBH and Beijing Defengrei Biotechnology Co. LTD.
- 8.1 List of Subsidiaries
- 12.1 Certification
- 12.2 Certification
- 13.1 Certification
- 13.2 Certification
- 15.1 Consent of Ernst & Young GMBH Wirtschaftsprufungsgesellschaft
- Download Excel data file
- View Excel data file
IFRX similar filings
Filing view
External links
Exhibit 15.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
(1) | Registration Statement (Form F-3 No. 333-239759) of InflaRx N.V. |
(2) | Registration Statement (Form S-8 No. 333-221656) pertaining to the InflaRx N.V. Long-Term Incentive Plan, InflaRx Stock Option Plan 2016, InflaRx Options Issued Pursuant To The Series B Financing Arrangement |
(3) | Registration Statement (Form S-8 No. 333-240185) pertaining to the InflaRx N.V. Long-Term Incentive Plan |
of our reports dated March 21, 2023, with respect to the consolidated financial statements of InflaRx N.V. and the effectiveness of internal control over financial reporting of InflaRx N.V. included in this Annual Report (Form 20-F) of InflaRx N.V. for the year ended December 31, 2022.
/s/ Ernst & Young GmbH Wirtschaftsprüfungsgesellschaft
Munich, Germany
March 22, 2023